Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue$1.26M$1.26M+15.5% vs Q1 2024 Net Income-$25.30M-$25.30MN/M vs Q1 2024 EPS Diluted-$0.07-$0.07N/M vs Q1 2024 Operating Income-$25,679,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Margins · derivedOperating margin-2034.8%+2112.8 pt vs Q1 2024
Net margin-2004.4%+2423.5 pt vs Q1 2024
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end